Inari Medical to Host Analyst and Investor Meeting Following PEERLESS RCT Presentation

NARI 10.07.2024

Full Press ReleaseSEC FilingsOur NARI Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.06.2025 - Stryker announces definitive agreement to acquire Inari Medical, Inc., providing entry into high-growth peripheral vascular segment
  • 01.03.2025 - Inari Medical to Present at the J.P. Morgan Healthcare Conference

Recent Filings

  • 01.17.2025 - SC 14D9 Solicitation, recommendation statements
  • 01.17.2025 - SC TO-T Tender offer statement by Third Party
  • 01.15.2025 - SC14D9C Written communication relating to third party tender offer
PDF Version

IRVINE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will host an analyst and investor meeting to discuss the PEERLESS study following its presentation at the Late-Breaking Clinical Trial Sessions at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. The analyst and investor meeting will be held on Tuesday, October 29, 2024 at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time.

Interested parties may access the live event by visiting the Events Section of the Inari investor relations website or by registeringhere. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on Inari’s website.

About Inari Medical, Inc.Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous disease, including venous thromboembolism, chronic venous disease and beyond. We are just getting started. Learn more atwww.inarimedical.comand connect with us onLinkedIn,X (Twitter), andInstagram.

Investor Contact:Marissa BychGilmartin Group LLCIR@inarimedical.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com